The approach should be considered to prevent leaks, which have been tied to increased stroke risks, Vivek Reddy says.
The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...
MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left ...
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...
MedPage Today on MSN
Pulsed field ablation tied to fewer LAA occluder leaks
Operators come to grips with LAA contractility in observational study ...
Applying radiofrequency (RF) energy to the left atrial appendage (LAA) in patients with residual leak after Watchman (Boston Scientific) implantation might be a viable way to eliminate peridevice ...
Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
BTIG analysts remain high on Boston Scientific (NYSE:BSX) following meetings with the company's management this week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results